Afrezza label

Afrezza

Afrezza Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

Ask a doctor before use if you have

  • a breathing problem such as emphysema or chronic bronchitis
  • difficulty in urination due to enlargement of the prostate gland
  • glaucoma

if you are

  • taking any drugs for asthma
  • taking sedatives or tranquilizers

When using this product

  • drowsiness may occur
  • avoid alcohol beverages
  • alcohol, sedatives and tranquilizers may increase the drowsiness effect
  • use caution when driving a motor vehicle or operating machinery
  • excitability may occur, especially in children

Stop use and ask a doctor if

  • side effects occur

Do not exceed recommended dosage.

If you are pregnant or breast-feeding, ask a health professional before use.

Keep out of the reach of children. In case of overdose, get medical help or contact a Poison Control

Center right away.

Ask a doctor before use if you have

  • a breathing problem such as emphysema or chronic bronchitis
  • difficulty in urination due to enlargement of the prostate gland
  • glaucoma

Stop use and ask a doctor if

  • side effects occur

Do not exceed recommended dosage.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Temporarily relieves the following symptoms associated with hay fever or other upper respiratory allergies

  • runny nose
  • sneezing
  • itching of the nose or throat
  • itchy, watery eyes

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Afrezza Manufacturers

  • Sanofi-aventis U.s. Llc
    Afrezza | Unifirst First Aid Corporation
    No Recall

    Afrezza | Unifirst First Aid Corporation

    Afrezza | Unifirst First Aid Corporation
    do not use more than directed

    Adults and children (12 years and older): Take 1 tablet every 4 to 6 hours as needed. Do not take more than 6 tablets in 24 hours, or as directed by a doctor.

    Children under 12 years: Do not give to children under 12 years of age.

  • Mannkind Corporation
    Afrezza | Mannkind Corporation
    No Recall

    Afrezza | Mannkind Corporation

    Afrezza | Mannkind Corporation

    2.1 Route of Administration

    AFREZZA should only be administered via oral inhalation using the AFREZZA Inhaler. AFREZZA is administered using a single inhalation per cartridge.

    2.2 Dosage Information

    Administer AFREZZA at the beginning of the meal.

    Dosage adjustment may be needed when switching from another insulin to AFREZZA [see Warnings and Precautions (5.2)].

    Starting Mealtime Dose:

    Insulin Naïve Individuals: Start on 4 units of AFREZZA at each meal. Individuals Using Subcutaneous Mealtime (Prandial) Insulin: Determine the appropriate AFREZZA dose for each meal by converting from the injected dose using Figure 1. Individuals Using Subcutaneous Pre-mixed Insulin: Estimate the mealtime injected dose by dividing half of the total daily injected pre-mixed insulin dose equally among the three meals of the day. Convert each estimated injected mealtime dose to an appropriate AFREZZA dose using Figure 1. Administer half of the total daily injected pre-mixed dose as an injected basal insulin dose.

    Figure 1. Mealtime AFREZZA Dose Conversion Table

    Mealtime Dose Adjustment

    Adjust the dosage of AFREZZA based on the individual's metabolic needs, blood glucose monitoring results and glycemic control goal.

    Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness [see Warnings and Precautions (5.3), and Use in Specific Populations (8.5, 8.6)] .

    Carefully monitor blood glucose control in patients requiring high doses of AFREZZA. If, in these patients, blood glucose control is not achieved with increased AFREZZA doses, consider use of subcutaneous mealtime insulin.

    2.3 AFREZZA Administration for Doses Exceeding 8 units

    For AFREZZA doses exceeding 8 units, inhalations from multiple cartridges are necessary. To achieve the required total mealtime dose, patients should use a combination of 4 unit and 8 unit cartridges. Examples of cartridge combinations for doses of up to 24 units are shown in Figure 1. For doses above 24 units, combinations of different multiple cartridges can be used.

    2.4 Dosage Adjustment due to Drug Interactions

    Dosage adjustment may be needed when AFREZZA is coadministered with certain drugs [see Drug Interactions (7)].

    2.5 Lung Function Assessment Prior to Administration

    AFREZZA is contraindicated in patients with chronic lung disease because of the risk of acute bronchospasm in these patients. Before initiating AFREZZA, perform a medical history, physical examination and spirometry (FEV1) in all patients to identify potential lung disease [see Contraindications (4) and Warnings and Precautions (5.1)].

    2.6 Important Administration Instructions

    See Patient Instructions for Use for complete administration instructions with illustrations.

    Keep the inhaler level and white mouthpiece on top and purple base on the bottom after a cartridge has been inserted into the inhaler. Loss of drug effect can occur if the inhaler is turned upside down, held with the mouthpiece pointing down, shaken (or dropped) after the cartridge has been inserted but before the dose has been administered. If any of the above occur, the cartridge should be replaced before use.